Grant Number:	2R01CA112520-06A2 Interpret this number
Primary Investigator:	Pasche, Boris
Organization:	University Of Alabama At Birmingham
Project Title:	Tgf-Beta Polymorphisms and Breast Cancer in Families
Fiscal Year:	2009

DESCRIPTION (provided by applicant): The Transforming Growth Factor Beta (TGF-ss) superfamily of growth factors regulates many cellular functions including cell growth, adhesion, migration, cell-fate determination and differentiation, and apoptosis. Ligands of the TGF-ss superfamily of growth factors comprises several TGF-ss isoforms, Activin isoforms, and Bone Morphogenetic Proteins, which are encoded by different genes but function through a similar receptor signaling system. The functionality of ligands, receptor proteins and SMAD intracellular messengers is critical for inhibitory signal transduction. There is, in this respect, growing evidence suggesting that common variants of the ligands, receptors and intracellular messengers of the TGF-ss superfamily may significantly modify breast cancer risk and outcome. We were the first to identify TGFBR1*6A, a common variant of the TGFBR1 gene. Our meta-analysis of fourteen case-control studies that included 6694 breast cancer cases and 8579 controls shows that TGFBR1*6A carriers have a significantly increased risk of breast cancer as compared with non- carriers. Overall, breast cancer risk is higher among TGFBR1*6A homozygotes (O.R. 1.40, 95% CI 1.04-1.88) than among TGFBR1*6A heterozygotes (O.R. 1.12, 95% CI 1.00-1.25) (Ptrend =8.41 x 10-4). A common variant of the TGFB1 gene has been associated with higher circulating levels of TGF-2 and increased TGF-ss secretion in vitro. A recent study conducted by the Breast Cancer Association Consortium (BCAC) has shown that breast cancer risk was increased among TGFB1 L10P heterozygotes (O.R. 1.07, 95% CI 1.02-1.13) and homozygotes (O.R. 1.16, 95% CI 1.08-1.25) (Ptrend = 2.8 x 10-5). Hence, naturally-occurring variants encoding for one ligand (TGFB1) and one receptor (TGFBR1) from the same signaling pathway are associated with breast cancer risk. These combined findings provide a strong rationale to comprehensively assess the TGF-2 signaling pathway in breast cancer. We propose to assess the association between haplotypes of the 65 genes of the TGF-2 superfamily and breast cancer risk using a family-based association study. Overall, we will perform a comprehensive genotypic analysis of the pathway in 5357 sister cases and sister controls from the NCI-sponsored Breast Cancer Family Registry. Genetic variants associated with breast cancer risk will be validated using the resources of BCAC. Validated SNPs will be further examined by the Consortium of Investigators of Modifiers of BRCA1 and BRCA2. To search for the causal variant(s) we will 1) re-sequence the validated region(s) in 200 patients that carry the risk haplotypes, 2) perform dense SNP genotyping. Using RNA extracted from lymphoblastoid cell lines we will functionally characterize the putative functionally-relevant SNPs independently and jointly. In secondary analyses, we will evaluate whether the associations of the various haplotypes and functionally-relevant mutations with breast cancer risk differ according to tumor stage, ER/PR and ERBB2 status and menopausal status. We will also determine the association of the TGF-2 superfamily SNPs with breast cancer outcomes. PUBLIC HEALTH RELEVANCE: There is growing evidence that subtle changes in genes of the TGF-2 pathway modify breast cancer risk. This project will study 65 genes of the TGF-2 pathway in 5357 women with breast cancer and their unaffected sisters and determine which genes are associated with breast cancer risk.




TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance.
Authors: Johansen A.M. , Forsythe S.D. , McGrath C.T. , Barker G. , Jimenez H. , Paluri R.K. , Pasche B.C. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2024-09-03 00:00:00.0; 30(17), p. 3676-3687.
PMID: 38916900
Related Citations

Inheritance Of Deleterious Mutations At Both Brca1 And Brca2 In An International Sample Of 32,295 Women
Authors: Rebbeck T.R. , Friebel T.M. , Mitra N. , Wan F. , Chen S. , Andrulis I.L. , Apostolou P. , Arnold N. , Arun B.K. , Barrowdale D. , et al. .
Source: Breast Cancer Research : Bcr, 2016-11-11 00:00:00.0; 18(1), p. 112.
PMID: 27836010
Related Citations

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Authors: Rebbeck T.R. , Mitra N. , Wan F. , Sinilnikova O.M. , Healey S. , McGuffog L. , Mazoyer S. , Chenevix-Trench G. , Easton D.F. , Antoniou A.C. , et al. .
Source: Jama, 2015-04-07 00:00:00.0; 313(13), p. 1347-61.
PMID: 25849179
Related Citations

TGF-ß: duality of function between tumor prevention and carcinogenesis.
Authors: Principe D.R. , Doll J.A. , Bauer J. , Jung B. , Munshi H.G. , Bartholin L. , Pasche B. , Lee C. , Grippo P.J. .
Source: Journal Of The National Cancer Institute, 2014 Feb; 106(2), p. djt369.
PMID: 24511106
Related Citations

TGFBR1 and cancer susceptibility.
Authors: Pasche B. , Pennison M.J. , Jimenez H. , Wang M. .
Source: Transactions Of The American Clinical And Climatological Association, 2014; 125, p. 300-12.
PMID: 25125747
Related Citations

Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.
Authors: Borate U. , Absher D. , Erba H.P. , Pasche B. .
Source: Expert Review Of Anticancer Therapy, 2012 Oct; 12(10), p. 1289-97.
PMID: 23176617
Related Citations

Association between IL6 -174G/C and cancer: A meta-analysis of 105,482 individuals.
Authors: Liu R.Y. , Song X. , Chen P. , Lei Z. , Miao J. , Yi N. , Zhang K. , Pasche B. , Zhang H.T. .
Source: Experimental And Therapeutic Medicine, 2012 Apr; 3(4), p. 655-664.
PMID: 22969947
Related Citations

Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk.
Authors: Kaklamani V. , Yi N. , Zhang K. , Sadim M. , Offit K. , Oddoux C. , Ostrer H. , Mantzoros C. , Pasche B. .
Source: Metabolism: Clinical And Experimental, 2011 Sep; 60(9), p. 1234-43.
PMID: 21397927
Related Citations

TGFBR1 signaling and breast cancer.
Authors: Moore-Smith L. , Pasche B. .
Source: Journal Of Mammary Gland Biology And Neoplasia, 2011 Jun; 16(2), p. 89-95.
PMID: 21461994
Related Citations

Whole-genome sequencing: a step closer to personalized medicine.
Authors: Pasche B. , Absher D. .
Source: Jama, 2011-04-20 00:00:00.0; 305(15), p. 1596-7.
PMID: 21505140
Related Citations

The role of the fat mass and obesity associated gene (FTO) in breast cancer risk.
Authors: Kaklamani V. , Yi N. , Sadim M. , Siziopikou K. , Zhang K. , Xu Y. , Tofilon S. , Agarwal S. , Pasche B. , Mantzoros C. .
Source: Bmc Medical Genetics, 2011-04-13 00:00:00.0; 12, p. 52.
EPub date: 2011-04-13 00:00:00.0.
PMID: 21489227
Related Citations

Bayesian analysis of genetic interactions in case-control studies, with application to adiponectin genes and colorectal cancer risk.
Authors: Yi N. , Kaklamani V.G. , Pasche B. .
Source: Annals Of Human Genetics, 2011 Jan; 75(1), p. 90-104.
PMID: 20846215
Related Citations

Statistical analysis of genetic interactions.
Authors: Yi N. .
Source: Genetics Research, 2010 Dec; 92(5-6), p. 443-59.
PMID: 21429274
Related Citations

Candidate gene association studies: successes and failures.
Authors: Pasche B. , Yi N. .
Source: Current Opinion In Genetics & Development, 2010 Jun; 20(3), p. 257-61.
PMID: 20417090
Related Citations

Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
Authors: Pasche B. , Wisinski K.B. , Sadim M. , Kaklamani V. , Pennison M.J. , Zeng Q. , Bellam N. , Zimmerman J. , Yi N. , Zhang K. , et al. .
Source: Journal Of Experimental & Clinical Cancer Research : Cr, 2010-05-25 00:00:00.0; 29, p. 57.
EPub date: 2010-05-25 00:00:00.0.
PMID: 20500843
Related Citations

Tgf-beta signaling alterations and colon cancer.
Authors: Bellam N. , Pasche B. .
Source: Cancer Treatment And Research, 2010; 155, p. 85-103.
PMID: 20517689
Related Citations

Cancer genetics. Introduction.
Authors: Pasche B. .
Source: Cancer Treatment And Research, 2010; 155, p. xi-xii.
PMID: 20698080
Related Citations

Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer.
Authors: Adrian K. , Strouch M.J. , Zeng Q. , Barron M.R. , Cheon E.C. , Honasoge A. , Xu Y. , Phukan S. , Sadim M. , Bentrem D.J. , et al. .
Source: Cancer Research, 2009-12-15 00:00:00.0; 69(24), p. 9169-74.
PMID: 19951995
Related Citations

TGFBR1 haplotypes and risk of non-small-cell lung cancer.
Authors: Lei Z. , Liu R.Y. , Zhao J. , Liu Z. , Jiang X. , You W. , Chen X.F. , Liu X. , Zhang K. , Pasche B. , et al. .
Source: Cancer Research, 2009-09-01 00:00:00.0; 69(17), p. 7046-52.
EPub date: 2009-09-01 00:00:00.0.
PMID: 19690145
Related Citations

One step forward toward identification of the genetic signature of glioblastomas.
Authors: Pasche B. , Myers R.M. .
Source: Jama, 2009-07-15 00:00:00.0; 302(3), p. 325-6.
PMID: 19602695
Related Citations

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
Authors: Rebbeck T.R. , Antoniou A.C. , Llopis T.C. , Nevanlinna H. , Aittomäki K. , Simard J. , Spurdle A.B. , KConFab , Couch F.J. , Pereira L.H. , et al. .
Source: Breast Cancer Research And Treatment, 2009 May; 115(1), p. 185-92.
PMID: 18523885
Related Citations

Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
Authors: Zeng Q. , Phukan S. , Xu Y. , Sadim M. , Rosman D.S. , Pennison M. , Liao J. , Yang G.Y. , Huang C.C. , Valle L. , et al. .
Source: Cancer Research, 2009-01-15 00:00:00.0; 69(2), p. 678-86.
PMID: 19147584
Related Citations

Role of polymorphisms in Adamantiades-Behçet's disease.
Authors: Kaklamani V.G. , Sadim M. , Koumantaki Y. , Kaklamanis P. , Pasche B. .
Source: The Journal Of Rheumatology, 2008 Dec; 35(12), p. 2376-8.
PMID: 18925687
Related Citations

Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis.
Authors: Varga J. , Pasche B. .
Source: Current Opinion In Rheumatology, 2008 Nov; 20(6), p. 720-8.
PMID: 18946334
Related Citations

Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk.
Authors: Kaklamani V.G. , Wisinski K.B. , Sadim M. , Gulden C. , Do A. , Offit K. , Baron J.A. , Ahsan H. , Mantzoros C. , Pasche B. .
Source: Jama, 2008-10-01 00:00:00.0; 300(13), p. 1523-31.
PMID: 18827209
Related Citations

Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer.
Authors: Valle L. , Serena-Acedo T. , Liyanarachchi S. , Hampel H. , Comeras I. , Li Z. , Zeng Q. , Zhang H.T. , Pennison M.J. , Sadim M. , et al. .
Source: Science (new York, N.y.), 2008-09-05 00:00:00.0; 321(5894), p. 1361-5.
EPub date: 2008-09-05 00:00:00.0.
PMID: 18703712
Related Citations

Familial colorectal cancer: a genetics treasure trove for medical discovery.
Authors: Pasche B. .
Source: Jama, 2008-06-04 00:00:00.0; 299(21), p. 2564-5.
PMID: 18523226
Related Citations

Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.
Authors: Kaklamani V.G. , Sadim M. , Hsi A. , Offit K. , Oddoux C. , Ostrer H. , Ahsan H. , Pasche B. , Mantzoros C. .
Source: Cancer Research, 2008-05-01 00:00:00.0; 68(9), p. 3178-84.
PMID: 18451143
Related Citations

Genetics and genomics for clinicians.
Authors: Fontanarosa P.B. , Pasche B. , DeAngelis C.D. .
Source: Jama, 2008-03-19 00:00:00.0; 299(11), p. 1364-5.
PMID: 18349101
Related Citations

TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation.
Authors: Rosman D.S. , Phukan S. , Huang C.C. , Pasche B. .
Source: Cancer Research, 2008-03-01 00:00:00.0; 68(5), p. 1319-28.
PMID: 18316594
Related Citations

Recent advances in breast cancer genetics.
Authors: Pasche B. .
Source: Cancer Treatment And Research, 2008; 141, p. 1-10.
PMID: 18274079
Related Citations

Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development.
Authors: Bian Y. , Knobloch T.J. , Sadim M. , Kaklamani V. , Raji A. , Yang G.Y. , Weghorst C.M. , Pasche B. .
Source: Human Molecular Genetics, 2007-12-15 00:00:00.0; 16(24), p. 3128-35.
EPub date: 2007-12-15 00:00:00.0.
PMID: 17890272
Related Citations

Targeting transforming growth factor-beta signaling.
Authors: Pennison M. , Pasche B. .
Source: Current Opinion In Oncology, 2007 Nov; 19(6), p. 579-85.
PMID: 17906455
Related Citations

Genetics and genomics: a call for papers.
Authors: DeAngelis C.D. , Fontanarosa P.B. , King M.C. , Pasche B. .
Source: Archives Of Surgery (chicago, Ill. : 1960), 2007 Sep; 142(9), p. 822.
PMID: 17875835
Related Citations

TGF-beta signaling alterations and susceptibility to colorectal cancer.
Authors: Xu Y. , Pasche B. .
Source: Human Molecular Genetics, 2007-04-15 00:00:00.0; 16 Spec No 1, p. R14-20.
PMID: 17613544
Related Citations

New insights into breast cancer genetics and impact on patient management.
Authors: Rosman D.S. , Kaklamani V. , Pasche B. .
Source: Current Treatment Options In Oncology, 2007 Feb; 8(1), p. 61-73.
PMID: 17634833
Related Citations